AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q90950

Application No.: 10/553,596

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A spiro-piperidine compound represented by formula (I):

wherein R¹ represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s) or a cyclic group which may have a substituent(s); and

ring A represents a tetrahydropyrimidin-2-(1H)-one group represented by the following formula which may have a substituent(s), in which 2,5-diketopiperazine having a spiro bond at the 3-position is excluded,

wherein R² represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s) in which the aliphatic hydrocarbon group is selected from the group consisting of ethyl, propyl, isopropyl, butyl, isobutyl, see-butyl, tert-butyl, pentyl, heptyl, octyl, C2-8 alkenyl and C2-8 alkynyl, a hydroxyl group which may be protected, carboxy which may be protected, carbamoyl which may be protected, or a cyclic group which may have a substituent(s) and,

R⁵ represents hydrogen, an aliphatic hydrocarbon group which may have a substituent(s), hydroxyl which may be protected, carboxy which may be protected, or a cyclic group which may have a substituent(s),

a salt thereof or a quaternary ammonium salt thereof-provided that 9-benzyl 1,3dimethyl 1,3,9-triazospiro[5.5]undecan 2-one; 1,3-dimethyl 1,3,9-triazaspiro[5.5]undecan 2AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q90950

Application No.: 10/553,596

one; 9-benzyl-1-methyl-1,3,9-triazospiro[5.5]undecan-2-one; and 1-methyl-1,3,9-triazaspiro[5.5]undecan-2-one are excluded.

- 2. (canceled).
- 3. (canceled).
- 4. (canceled).
- 5. (canceled).
- 6. (canceled).
- 7. (previously presented): The spiro-piperidine compound according to claim 1, wherein R¹ is a C1-10 aliphatic hydrocarbon group which may have a substituent(s), a salt thereof or a quaternary ammonium salt thereof.
- 8. (currently amended): The A spiro-piperidine compound according to claim-1 represented by formula (I):



wherein R^1 is a 5- to 10-membered monocyclic or bicyclic cyclic group which may have a substituent(s), and

ring A represents a tetrahydropyrimidin-2-(1H)-one group which may have a substituent(s), in which 2,5-diketopiperazine having a spiro bond at the 3-position is excluded

a salt thereof or a quaternary ammonium salt thereof.

- 9. (previously presented): The spiro-p:peridine compound according to claim 1, wherein \mathbb{R}^1 is alkyl having from 1 to 6 carbon atoms substituted with a 3- to 10-membered monocyclic or bicyclic cyclic group which may have a substituent(s), a salt thereof or a quaternary ammonium salt thereof.
- 10. (previously presented): A pharmaceutical composition which comprises the spiro-piperidine compound according to claim 1, a salt thereof or a quaternary ammonium salt thereof, and a pharmaceutically acceptable carrier or diluent.

11. (canceled).

AMENDMENT UNDER 37 C.F.R. § 1.116 Attorney Docket No.: Q90950

Application No.: 10/553,596

12. (canceled).

13. (canceled).

14. (canceled).

15. (canceled).

16. (canceled).

17. (canceled).

18. (canceled).

19. (withdrawn) A method for treating diseases selected from the group consisting of asthma, nepohritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, rejection in organ transplantation, immunosuppression, psoriasis, multiple sclerosis, infection with human immunodeficiency virus, atopic dermatitis, uticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacterial infection, diabetes mellitus, cancer metastasis and arteriosclerosis, which comprises administering to a mammal an effective amount of the spiro-piperidine compound according to claim 1, a salt thereof or a quaternary ammonium salt thereof.

- 20. (canceled).
- 21. (previously presented): The spiro-piperidine compound according to claim 1, wherein \mathbb{R}^2 is an aliphatic hydrocarbon group which may have a substituent(s) in which the aliphatic hydrocarbon group is selected from the group consisting of ethyl, propyl, isopropyl, butyl, isobutyl, see-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, C2-8 alkenyl and C2-8 alkynyl.